Arvinas, Inc. (NASDAQ:ARVN) Short Interest Update

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 8,600,000 shares, a growth of 8.6% from the March 15th total of 7,920,000 shares. Based on an average daily volume of 735,200 shares, the short-interest ratio is currently 11.7 days.

Analysts Set New Price Targets

ARVN has been the topic of several recent research reports. Citigroup downgraded Arvinas from a "buy" rating to a "neutral" rating and raised their price target for the stock from $36.00 to $55.00 in a report on Wednesday, February 14th. Wedbush raised their price target on Arvinas from $33.00 to $59.00 and gave the stock an "outperform" rating in a report on Wednesday, February 28th. Oppenheimer restated an "outperform" rating and issued a $80.00 target price (down from $95.00) on shares of Arvinas in a research report on Wednesday, February 28th. Wells Fargo & Company upgraded Arvinas from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $25.00 to $63.00 in a research report on Tuesday, December 19th. Finally, Leerink Partnrs restated an "outperform" rating on shares of Arvinas in a research report on Thursday, February 22nd. Two analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $59.73.

Arvinas Price Performance

ARVN traded down $1.57 during trading on Monday, reaching $34.72. 649,646 shares of the stock traded hands, compared to its average volume of 727,035. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of -5.34 and a beta of 1.94. Arvinas has a fifty-two week low of $13.57 and a fifty-two week high of $53.08. The stock's 50-day simple moving average is $44.45 and its two-hundred day simple moving average is $33.85.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.15) by ($1.38). The firm had revenue of ($43.10) million for the quarter, compared to analyst estimates of $38.91 million. Arvinas had a negative net margin of 185.09% and a negative return on equity of 70.24%. During the same period in the previous year, the business posted ($1.56) EPS. Research analysts anticipate that Arvinas will post -5.73 earnings per share for the current fiscal year.

Insider Activity at Arvinas

In related news, CFO Sean A. Cassidy sold 1,702 shares of the stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $47.05, for a total value of $80,079.10. Following the completion of the transaction, the chief financial officer now owns 181,916 shares of the company's stock, valued at $8,559,147.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Arvinas news, CFO Sean A. Cassidy sold 1,702 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total transaction of $80,079.10. Following the transaction, the chief financial officer now owns 181,916 shares of the company's stock, valued at approximately $8,559,147.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Ronald Peck sold 1,699 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total value of $79,937.95. Following the transaction, the insider now directly owns 67,516 shares in the company, valued at approximately $3,176,627.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,597 shares of company stock valued at $404,489. Insiders own 2.55% of the company's stock.

Institutional Trading of Arvinas

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in Arvinas by 9.6% during the second quarter. BlackRock Inc. now owns 4,903,469 shares of the company's stock valued at $121,704,000 after buying an additional 427,871 shares in the last quarter. FMR LLC raised its holdings in Arvinas by 10.6% during the third quarter. FMR LLC now owns 4,868,295 shares of the company's stock valued at $95,613,000 after buying an additional 466,667 shares in the last quarter. Vanguard Group Inc. raised its holdings in Arvinas by 5.3% during the fourth quarter. Vanguard Group Inc. now owns 4,851,390 shares of the company's stock valued at $199,683,000 after buying an additional 243,167 shares in the last quarter. RTW Investments LP bought a new position in Arvinas during the fourth quarter valued at about $173,427,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in Arvinas by 42.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,832,123 shares of the company's stock valued at $157,731,000 after buying an additional 1,143,452 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company's stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.